A genetic discovery could pave the way to earlier diagnosis of ovarian cancer and personalised treatments, scientists claim.

Researchers identified six RNA ‘messenger’ molecules that are found in ovarian cancer cells but not healthy cells.

Spotting the molecules could help diagnose ovarian cancer in its early stages, before it produces any symptoms.

A number of them are also linked to unique proteins that could be targeted with new drugs, according to the researchers. Messenger RNA (mRNA) is a molecular cousin of DNA that carries information from the genetic code to protein-making machinery in cells.

Lead scientist Christian Barrett, from the University of California at San Diego, the US, said: “We were inspired by many studies aimed at using DNA to detect cancer. But we wondered if we could instead develop an ovarian cancer detection test based on tumour-specific mRNA that has disseminated from cancer cells to the cervix and can be collected during a routine Pap (smear) test.”

We were inspired by many studies aimed at using DNA to detect cancer

The advantage of using mRNA rather than DNA for diagnosis is that it is much more visible, said the researchers whose findings are reported in the journal Proceedings of the National Academy of Sciences.

A cancer cell might harbour just one or a few copies of a DNA mutation, but mRNA variants can occur in hundreds to thousands of copies per cell.

The findings, made in the laboratory, are just the first step towards developing a method of mRNA diagnosis for ovarian cancer, the researchers pointed out.

Co-author Cheryl Saenz, also from the University of California at San Diego, said: “Clinical trials will need to be conducted on women to confirm the presence of these markers in women that we know have cancer, as well as to document the absence of the markers in women that do not have ovarian cancer.”

Ovarian cancer is often missed until it has reached a late stage, by which time treatment is difficult.

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.